Publications found:
164,030
Sort by:
Textron Inc. - Strategic Snapshot & SWOT Analysis - Q4 2011
US$ 150.00
SWOT Analysis is a framework used extensively for an assessment of the internal as well as external business environment as part of the strategic or corporate planning process. The framework generates...
October 2011
15 pages
EADS N.V. - Strategic Snapshot & SWOT Analysis - Q4 2011
US$ 150.00
SWOT Analysis is a framework used extensively for an assessment of the internal as well as external business environment as part of the strategic or corporate planning process. The framework generates...
October 2011
15 pages
Thales S.A. - Strategic Snapshot & SWOT Analysis - Q4 2011
US$ 150.00
SWOT Analysis is a framework used extensively for an assessment of the internal as well as external business environment as part of the strategic or corporate planning process. The framework generates...
October 2011
15 pages
Daimler AG - Strategic Snapshot & SWOT Analysis - Q4 2011
US$ 150.00
SWOT Analysis is a framework used extensively for an assessment of the internal as well as external business environment as part of the strategic or corporate planning process. The framework generates...
October 2011
15 pages
Volvo AB - Strategic Snapshot & SWOT Analysis - Q4 2011
US$ 150.00
SWOT Analysis is a framework used extensively for an assessment of the internal as well as external business environment as part of the strategic or corporate planning process. The framework generates...
October 2011
15 pages
Scania AB - Strategic Snapshot & SWOT Analysis - Q4 2011
US$ 150.00
SWOT Analysis is a framework used extensively for an assessment of the internal as well as external business environment as part of the strategic or corporate planning process. The framework generates...
October 2011
15 pages
PACCAR Inc. - Strategic Snapshot & SWOT Analysis - Q4 2011
US$ 150.00
SWOT Analysis is a framework used extensively for an assessment of the internal as well as external business environment as part of the strategic or corporate planning process. The framework generates...
October 2011
15 pages
Iveco S.p.A. - Strategic Snapshot & SWOT Analysis - Q4 2011
US$ 150.00
SWOT Analysis is a framework used extensively for an assessment of the internal as well as external business environment as part of the strategic or corporate planning process. The framework generates...
October 2011
15 pages
ASTRAZENECA - Seroquel XR: Para IV Settled with Handa, More to come
US$ 90.00
AstraZeneca today announced that it has settled paragraph IV litigation for Seroquel XR with Handa pharmaceuticals, who has the first to filer status ... settlement Handa will launch Seroquel XR generics only after November 2016. While litigation is ongoing with other Para-IV filers and a court decision ...
September 2011
2 pages
The 2011 Leading Chemical Companies Facilities and Employees
US$ 1,480.00
... U.S. and abroad. Manufacturing practices. New plants under construction. U.S. and international work force size and distribution development. The companies analyzed in the report: BASF, Bayer, BP Chemical, Dow, DuPont, ExxonMobil, Formosa, ICI, Mitsubishi Chemical, Shell, and Total. Contains 63 pages
September 2011
63 pages
The 2011 Leading Chemical Companies R&D Expenditures and Major Programs
US$ 2,000.00
... company, the report provides: Estimated R&D budget. Research facilities and staff. New technologies, products and applications in development. The companies analyzed in the report: BASF, Bayer, BP Chemical, Dow, DuPont, ExxonMobil, Formosa, ICI, Mitsubishi Chemical, Shell, and Total. Contains 44 pages
September 2011
44 pages
The 2011 Leading Chemical Companies Collaborative Arrangements
US$ 1,480.00
... ventures, distribution, OEM and licensing partners, both industrial and academic. Terms of collaborative agreements and specific products involved. The companies analyzed in the report: BASF, Bayer, BP Chemical, Dow, DuPont, ExxonMobil, Formosa, ICI, Mitsubishi Chemical, Shell, and Total. Contains 52 pages
September 2011
52 pages
The 2011 Leading Chemical Companies Business Organizations and Senior Management Profiles
US$ 1,480.00
... . Recent acquisitions, divestitures and significant organizational changes. Current organizational structure. Background of key executives. The companies analyzed in the report: BASF, Bayer, BP Chemical, Dow, DuPont, ExxonMobil, Formosa, ICI, Mitsubishi Chemical, Shell, and Total. Contains 125 pages
September 2011
125 pages
The 2011 Leading Orthopedics Companies Collaborative Arrangements
US$ 1,480.00
... ventures, distribution, O.E.M. and licensing partners, both industrial and academic. Terms of collaborative agreements and specific products involved. The companies analyzed in the report: Aesculap, Biomet, ConMed, J&J, Medtronic, Smith & Nephew, Stryker, Synthes, Wright Medical, and Zimmer. Contains 42 ...
September 2011
42 pages
The 2011 Leading Orthopedics Companies Product Portfolio Analyses
US$ 1,400.00
Each company's analysis provides: Review of major product lines. Specifications and features of current products. The companies analyzed in the report: Aesculap, Biomet, ConMed, J&J, Medtronic, Smith & Nephew, Stryker, Synthes, Wright Medical, and Zimmer. Contains 158 pages
September 2011
158 pages
Pharmasset - Tapping Both IFN and IFN-Free Opportunities
US$ 140.00
... daily NS5A inhibitor (BMS-790052) +Peg-IFN/RBV. Efficacy data of BMS-790052 raises ... NS5A inhibitor) - Once daily w/o IFN. PSI-7977+ Peg-IFN/RBV have shown advantage over the ... IFN-free combinations. For more details, please read our report released on 21th September, 2011 on VRUS titled “Tapping Both IFN and IFN ...
September 2011
7 pages
ALEXION - Great Expectations From Label Expansion
US$ 140.00
We have a positive expectation for the approval of Eculizumab (L, Soliris, Paroxysmal Nocturnal Hemoglobinuria) in Atypical ... more details, please read our report released on September 16, 2011 on Alexion (ALXN), titled “Great Expectations From Label Expansion”.
September 2011
4 pages
ARQULE - Read-Out Only in 2013
US$ 140.00
... . It is an attractive acquisition target due to…. For more details, please read our report released on 13th September, 2011 on ARQL titled “Read-Out Only in 2013”.
September 2011
4 pages
ARDEA - Entering the Pivotal Phase
US$ 140.00
After a long wait, Ardea (RDEA) reached an agreement with the FDA on the proposed PhIII ... in the report released on 12th September, 2011 on RDEA titled “Entering the Pivotal Phase”. For more details please ask for our initiation ...
September 2011
3 pages
DNA Sequencing: Role in Clinical Laboratories
US$ 680.00
... , detection, gene profiling, and expression, polymorphism, screening, protein interaction networks, and others. Sequencing is expected to continue playing a major role in clinical laboratories, e.g., in detecting resistance mutations in viruses and bacteria, especially because of the rising availability of ...
August 2011
15 pages
Nestle: Performance, Capabilities, Goals and Strategies in the Worldwide Dairy Market
US$ 1,520.00
... competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs. The report presents a comprehensive analysis of the company’s performance, capabilities, goals and strategies in the global dairy market. Contains 63 pages and 11 tables
August 2011
63 pages
Business Snapshot & SWOT Analysis - Caterpillar Inc.
US$ 150.00
SWOT Analysis is a framework used extensively for an assessment of the internal as well as external business environment as part of the strategic or corporate planning process. The framework generates...
August 2011
15 pages
Business Snapshot & SWOT Analysis - Komatsu Ltd.
US$ 150.00
SWOT Analysis is a framework used extensively for an assessment of the internal as well as external business environment as part of the strategic or corporate planning process. The framework generates...
August 2011
15 pages